

FINANCIAL STATEMENTS (Un-Audited)
For the period from 01.07.2016 to 31.12.2016



THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.
Tanim Center, 3 Asad Gate, Mirpur Road, Mohammadpur,
Dhaka-1207, Bangladesh.

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.

Tanim Center, 3 Asad Gate, Mirpur Road, Mohammadpur, Dhaka-1207


Muhtaram Shareholder(s),
Assalamu Alaikum Wa Rahmatullah,

As per rule 13 of Securities and Exchange Rules-1987 and Bangladesh Accounting Standard (BAS) - 34, we are pleased to enclose herewith the un-audited Statement of Financial Position as at 31st December 2016, the Statement of Profit or Loss and other Comprehensive Income, Statement of Cash Flows and Statement of Changes in Equity for the half-year ended 31st December, 2016 for your kind perusal.


STATEMENT OF FINANCIAL POSITION (Un-Audited)

As at 31st December, 2016

	Notes	Amount in Taka	
		As at 31.12.2016	As at 30.06.2016
ASSETS:			
Non-Current Assets:			
Property, Plant and Equipment	02	1,018,631,166	951,723,570
Investment in Marketable Securities (AFS)	03	331,620,618	326,031,002
Investment	03.01	1,750,000	1,750,000
		522,311,696	451,450,553
Current Assets :			
Inventories	04	224,324,288	183,711,938
Accounts Receivable		15,525,739	8,101,219
Advances, Deposits & Prepayments	05	107,985,653	90,331,492
Cash & Cash Equivalents	06	174,476,016	169,305,904
		1,874,313,480	1,730,955,125
TOTAL ASSETS		<u>1,874,313,480</u>	<u>1,730,955,125</u>
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Shareholders' Equity:			
Share Capital		258,211,800	224,532,000
Net Gain on Marketable Securities (AFS)	03	264,747,474	259,716,820
Tax Holiday Reserve		4,392,110	4,392,110
Retained Earnings	07	464,200,707	380,790,698
		991,552,091	869,431,628
Non-Current Liabilities			
Deferred Tax Liability	08	314,162,415	208,436,968
	09	75,594,653	68,335,622
		493,004,321	584,750,907
Current Liabilities:			
Bank & Other Finance	10	205,422,373	238,883,883
Accounts and Other Payables	11	287,581,948	345,867,024
		1,874,313,480	1,730,955,125
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		<u>1,874,313,480</u>	<u>1,730,955,125</u>
Net Asset Value (NAV) per Share (restated-2015)		38.40	33.67


(Md. Jasim Uddin, FCA)
Chief Financial Officer


(Md. Shahid Farooqui, FCS)
Company Secretary


(Prof. Dr. Shah Md. Bulbul Islam)
Director

Dated, Dhaka
23-Jan-17


(Prof. Dr. A.K.M. Sadrul Islam)
Managing Director



(Shah Abdul Hannan)
Chairman


THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Un-Audited)
For the Half-year ended 31st December, 2016


Amount in Taka				
Notes	For the half-year (July 01, 2016 to December 31, 2016)	For the half-year (July 01, 2015 to December 31, 2015)	For the Quarter (October 01, 2016 to December 31, 2016)	For the Quarter (October 01, 2015 to December 31, 2015)
Revenue	1,978,586,249	1,688,157,195	1,045,838,834	953,861,975
Cost of goods sold	<u>(1,177,512,003)</u>	<u>(1,001,348,635)</u>	<u>(622,203,150)</u>	<u>(562,377,259)</u>
Gross Profit	801,074,246	686,808,560	423,635,684	391,484,716
Operating Expenses:				
Administrative expenses	13 (46,366,506)	(37,091,388)	(23,350,582)	(18,078,791)
Selling & Distribution expenses	14 <u>(565,536,172)</u>	<u>(482,844,899)</u>	<u>(272,579,392)</u>	<u>(250,437,868)</u>
	<u>(611,902,678)</u>	<u>(519,936,287)</u>	<u>(295,929,974)</u>	<u>(268,516,659)</u>
Operating Profit	189,171,568	166,872,273	127,705,710	122,968,057
Financial charges	(7,923,834)	(4,163,304)	(5,827,671)	(2,890,713)
Other income	<u>2,036,052</u>	<u>4,854,936</u>	<u>1,712,682</u>	<u>4,403,616</u>
Workers' P.P. Fund & Welfare Fund	183,283,786	167,563,905	123,590,721	124,480,960
	<u>(8,727,799)</u>	<u>(7,979,233)</u>	<u>(5,885,272)</u>	<u>(5,927,664)</u>
Net Profit before tax	174,555,987	159,584,672	117,705,449	118,553,296
Less: Income tax expenses				
Current tax	09 (36,099,747)	(26,971,080)	(22,599,495)	(16,713,236)
Deferred tax:	6,700,069	(8,618,275)	6,914,346	(3,199,703)
	<u>(29,399,678)</u>	<u>(35,589,355)</u>	<u>(15,685,149)</u>	<u>(19,912,939)</u>
Net Profit after tax	145,156,309	123,995,317	102,020,300	98,640,357
Other Comprehensive Income:				
Change in fair value of Marketable Securities (AFS)	03 5,589,616	116,966,330	(14,251,633)	(30,811,635)
Deferred tax	<u>(558,962)</u>	<u>(11,696,632)</u>	<u>1,425,163</u>	<u>3,081,164</u>
Total other comprehensive income for the period, net of tax	<u>5,030,654</u>	<u>105,269,698</u>	<u>(12,826,470)</u>	<u>(27,730,471)</u>
Total other comprehensive income for the period 31st December, 2016	<u>150,186,963</u>	<u>229,265,015</u>	<u>89,193,830</u>	<u>70,909,886</u>
Earnings per share-basic (restated-2015)	<u>5.62</u>	<u>4.80</u>	<u>3.95</u>	<u>3.82</u>


(Md. Jasim Uddin, FCA)
Chief Financial Officer


(Md. Shahid Farooqui, FCS)
Company Secretary


(Prof. Dr. Shah Md. Bulbul Islam)
Director


Dated, Dhaka 23-Jan-17 (Prof. Dr. A.K.M. Sadrul Islam)
Managing Director


(Shah Abdul Hannan)
Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.

STATEMENT OF CHANGES IN EQUITY (Un-Audited)

For the Half-year ended 31st December, 2016

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (Unrealized)	Retained Earnings	Total
Balance as at 1st January, 2016	224,532,000	4,392,110	245,913,549	358,108,009	832,945,668
Total Comprehensive Income/(Loss)-2016	-	-	13,803,271	78,815,689	92,618,960
Interim Dividend for the year, 2015 (Cash -25%)				(56,133,000)	(56,133,000)
Balance as at 1st July, 2016	224,532,000	4,392,110	259,716,820	380,790,698	869,431,628
Total Comprehensive Income/(Loss) for the period ended 30th June, 2016			5,030,654	145,156,309	150,186,963
Dividend for the half year, 2016 (Cash-12.50%)				(28,066,500)	(28,066,500)
Dividend for the 18th months, 2016 (Stock-15%)	33,679,800			(33,679,800)	-
Balance as at 31st December, 2016	258,211,800	4,392,110	264,747,474	464,200,707	991,552,091

STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (Un-Audited)

For the Half-year ended 31st December, 2015


Restated

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (Unrealized)	Retained Earnings	Total
Balance as at 1st January, 2015	213,840,000	4,392,110	206,217,741	254,894,853	679,344,704
Total Comprehensive Income/(Loss) for the period ended 30th June, 2015			(65,573,888)	54,061,838	(11,512,050)
Dividend for the year, 2014 (Cash-30%)				(64,152,000)	(64,152,000)
Dividend for the year, 2014 (Stock-05%)	10,692,000			(10,692,000)	
Balance as at 1st July, 2015	224,532,000	4,392,110	140,643,853	234,112,691	603,680,654
Total Comprehensive Income/(Loss) for the period ended 31st December, 2015	-	-	105,269,696	123,995,318	229,265,014
Balance as at 31st December, 2015	224,532,000	4,392,110	245,913,549	358,108,009	832,945,668


(Md. Jasim Uddin, FCA)
Chief Financial Officer


(Md. Shahid Farooqui, FCS)
Company Secretary


(Prof. Dr. Shah Md. Bulbul Islam)
Director

Dated, Dhaka
23-Jan-17


(Prof. Dr. A.K.M. Sadrul Islam)
Managing Director


(Shah Abdul Hannan)
Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.
STATEMENT OF CASH FLOWS (Un-Audited)
For the Half-year ended 31st December, 2016

	Amount in Taka	
	Half-year ended 31.12.2016	Half-year ended 31.12.2015
Cash Flow From Operating Activities:		
Collection from customers & others	1,969,125,677	1,685,757,074
Payment for cost & expenses	(1,860,196,389)	(1,486,938,102)
Miscellaneous Income	321,540	150,640
Cash generated from operations	109,250,828	198,969,612
Income tax paid	(18,198,289)	(29,456,351)
Financial charges	(7,923,834)	(4,163,304)
Net cash provided by operating activities	83,128,705	165,349,957
Cash Flow From Investing Activities:		
Purchase of fixed assets	(110,352,781)	(365,402,629)
Proceeds from sales of motor vehicles	-	2,378,400
Dividend income	-	3,817,359
Profit from bank deposits & investment	1,714,512	469,207
Net cash used in investing activities	(108,638,269)	(358,737,663)
Cash Flow From Financing Activities:		
Payment of dividend	(85,281,550)	(45,977,684)
Long term finance received/(paid) from bank (net)	84,780,828	86,188,355
Short term finance received/(paid) from bank (net)	31,180,398	167,233,052
Net cash flow from financing activities	30,679,676	207,443,723
Increase/(decrease) in cash and cash equivalents	5,170,112	14,056,017
Cash and cash equivalents at the opening	169,305,904	149,542,827
Cash and cash equivalents at the closing	<u>174,476,016</u>	<u>163,598,844</u>


Net operating cash flow per share (NOCFPS)
(restated-2015)

3.22

6.40


(Md. Jasim Uddin, FCA)
Chief Financial Officer


(Md. Shahid Farooqui, FCS)
Company Secretary


(Prof. Dr. Shah Md. Bulbul Islam)
Director

Dated, Dhaka
23-Jan-17


(Prof. Dr. A.K.M. Sadrul Islam)
Managing Director


(Shah Abdul Hannan)
Chairman

The Ibn Sina Pharmaceutical Industry Ltd.
Selected Notes to the Financial Statements (Un-Audited)

For the Half-year ended 31st December, 2016

Selected Explanatory Notes

01 (a). Basis of Preparation of Financial Statements

These financial Statements have been prepared in line with the accounting policies and methods of computations of the annual financial statements prepared and published for the year ended 30th June, 2016. These interim financial statements includes only selected explanatory notes as deemed appropriate for understanding of these un-audited financial statements.

01 (b). Reporting

This half-yearly financial report has been prepared based on Bangladesh Accounting Standard (BAS)-34 "Interim Financial Reporting".

01 (c) Earnings Per Share (EPS)

Earnings per share has been calculated based on number of shares outstanding for the period ended December 31, 2016 and profit for the same period. The number of shares outstanding for the period was 25.821 million. Earnings per share for the corresponding period of 2015 has also been calculated based on 25.821 million shares. No diluted earnings per share is required to be calculated as there was no scope for dilution during the period under review.

01 (e). Subsequent events

No Material events occurred after the reporting date, non disclosure of which could affect the stakeholders to make proper valuation and decision.

Previous period figures have been re-arranged to conform to current period's presentation, where considered necessary.

02. PROPERTY, PLANT AND EQUIPMENT:

Cost/Revaluation

Opening Balance

Addition during the period

Disposal/Adjustment during the period

Accumulated Depreciation

Opening Balance

Charged during the period

Disposal/Adjustment during the period

Written Down Value (WDV)

Amount in Taka	
As at 31.12.2016	As at 30.06.2016

1,352,403,379	1,234,493,763
110,352,781	121,948,368
-	(4,038,752)
1,462,756,160	1,352,403,379

400,679,809	364,007,758
43,445,185	40,281,746
-	(3,609,695)
444,124,994	400,679,809

1,018,631,166	951,723,570
----------------------	--------------------

03. INVESTMENT IN MARKETABLE SECURITIES (FAIR VALUE):

Sl No.	Name of Company Share/Bond	No. of Shares /Bond Held	Face Value Per Share /Bond	Cost of Holding	Average Cost	Quoted Rate Per Share/ Bond as on 31.12.16	Total Market value of shares/ Bond as on 31.12.16	Unrealized Gain/(Loss)
1	Islami Bank Bangladesh Ltd. (IBBL)- in shares	11,013,991	10	32,866,758	2.98	29.70	327,115,533	294,248,775
2	Islami Bank Bangladesh Ltd. (IBBL)-in Mudaraba Perpetual Bond (MPB)	4,590	1,000	4,590,000	1,000	981.50	4,505,085	(84,915)
	Total Taka			37,456,758			331,620,618	294,163,860

		Amount in Taka	
		As at 31.12.2016	As at 30.06.2016
a)	NET GAIN/(LOSS) ON MARKETABLE SECURITIES (AFS) :		
	Unrealized Gain/(Loss) Position (Closing)	294,163,860	288,574,244
	Deferred tax on gain on marketable securities (AFS)	(29,416,386)	(28,857,424)
		264,747,474	259,716,820
b)	CHANGE IN FAIR VALUE OF MARKETABLE SECURITIES (AFS) :		
	Unrealized Gain/(Loss) Position (Closing)	294,163,860	288,574,244
	Unrealized Gain/(Loss) Position (Opening)	(288,574,244)	(273,237,277)
		5,589,616	15,336,967
03.01	INVESTMENT		
	IBN SINA Consumer Products Ltd. (35% of total share holding)	1,750,000	1,750,000
04.	INVENTORIES:		
	Raw materials	78,545,598	63,422,056
	Packing materials	60,543,312	45,417,891
	Work-in-process	31,295,804	28,472,242
	Finished goods	51,602,019	45,165,430
	Physicians' samples & others	2,337,555	1,234,319
		224,324,288	183,711,938
05.	ADVANCES, DEPOSITS & PRE-PAYMENTS :		
	<i>This is recoverable in cash or for value to be received and consists of as follows :</i>		
	a. Advances against-		
	Salary	1,420,401	1,640,511
	Expenses/Works	4,028,430	3,787,220
	Sales centre rent	3,581,047	3,816,457
	Motor cycles - to employees	6,001,529	5,787,319
	Income Tax	80,413,525	63,186,981
	Others	243,665	53,935
		95,688,617	78,272,323
	b. Deposits -		
	Security money	5,125,931	4,964,521
	c. Pre-payments -		
	Value Added Tax (VAT)	6,660,056	6,120,056
	Insurance premium	511,049	974,592
		7,171,105	7,094,648
	(a+b+c)	107,985,653	90,331,492
06.	CASH & CASH EQUIVALENTS:		
	Cash in hand & Bank Balance	168,432,666	163,369,304
	Imprest Cash	6,043,350	5,936,600
		174,476,016	169,305,904
07.	RETAINED EARNINGS :		
	Retained Earnings	380,790,698	358,108,009
	Dividend Paid	(61,746,300)	(56,133,000)
	Add : Surplus during the period/year	145,156,309	78,815,688
		464,200,707	380,790,698
08.	NON-CURRENT LIABILITIES:		
	Long Term Finance-Net off current maturity	271,444,914	186,664,066
	Retirement Benefit Obligation	42,717,501	21,772,882
		314,162,415	208,436,968

09. DEFERRED TAX ASSET/LIABILITY :

Deferred Tax Asset/Liability represents deferred tax recognized as asset/liability the movement of which is as below:

a) Deferred tax liability on net temporary differences:

Balance as at 1st January	39,478,198	16,430,230
Deferred tax expenses/(income)	6,700,069	23,047,968
	46,178,267	39,478,198

b) Deferred tax liability on change in AFS :

Balance as at 1st January	28,857,424	27,323,728
Addition/(Less) during the year	558,962	1,533,696
	29,416,386	28,857,424
Deferred tax liability at closing balance (a+b)	75,594,653	68,335,622

10. BANK & OTHER FINANCE :

Short Term Finance	154,853,867	111,041,160
Long Term Finance-Current maturity	12,632,309	25,264,618
Deposits	13,101,191	19,255,848
Other Finance	24,835,006	83,322,257
	205,422,373	238,883,883

11. ACCOUNTS AND OTHER PAYABLES:

Payable for Suppliers	134,765,153	179,930,531
Accrued Expenses	67,303,104	115,550,805
Income Tax Liability	85,513,691	50,385,688
	287,581,948	345,867,024

Amount in Taka

For the half-year (July 01, 2016 to December 31, 2016)	For the half-year (July 01, 2015 to December 31, 2015)
--	--

12. COST OF GOODS SOLD :

Materials	953,665,707	819,997,235
Factory Overhead	187,572,411	159,343,116
Depreciation	36,273,885	22,008,284
	1,177,512,003	1,001,348,635


13. ADMINISTRATIVE EXPENSES :


Salary, wages & Allowances	28,092,754	20,688,395
Repairs & Maintenance	1,901,371	2,114,411
Travelling & Conveyance	1,175,466	378,670
AGM, Fees and Others	601,581	1,124,928
Depreciation	2,564,081	2,086,217
Other Expenses	12,031,253	10,698,767
	46,366,506	37,091,388

14. SELLING & DISTRIBUTION EXPENSES :

Salary, wages & Allowances	351,610,759	301,796,031
Travelling & Conveyance	1,829,033	1,248,411
Market Survey & Research and Product development	2,345,415	1,661,858
Field personnel expenses	71,426,011	69,178,616
Sample, Literature & Promotional Expenses	8,594,148	7,242,351
Delivery Expenses	58,210,012	55,763,733
Depreciation	4,607,219	3,047,658
Other Expenses	66,913,575	42,906,241
	565,536,172	482,844,899


(Md. Jasim Uddin, FCA)
Chief Financial Officer


(Md. Shahid Farooqui, FCS)
Company Secretary


(Prof. Dr. Shah Md. Bulbul Islam)
Director

Dated, Dhaka
23-Jan-17


(Prof. Dr. A.K.M. Sadrul Islam)
Managing Director


(Shah Abdul Hannan)
Chairman